| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies
|
Cosmai, Laura
|
|
|
|
2 |
p.
|
artikel
|
| 2 |
Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis
|
Peleg Hasson, S.
|
|
|
|
2 |
p.
|
artikel
|
| 3 |
Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)
|
Ferrari, A.
|
|
|
|
2 |
p.
|
artikel
|
| 4 |
Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine
|
van de Haar, Joris
|
|
|
|
2 |
p.
|
artikel
|
| 5 |
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆
|
Tarhini, A.A.
|
|
|
|
2 |
p.
|
artikel
|
| 6 |
An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer
|
Thiery-Vuillemin, A.
|
|
|
|
2 |
p.
|
artikel
|
| 7 |
Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic
|
Araújo, N.
|
|
|
|
2 |
p.
|
artikel
|
| 8 |
A new era of oncology through artificial intelligence
|
Curioni-Fontecedro, Alessandra
|
|
|
|
2 |
p.
|
artikel
|
| 9 |
Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options
|
Ay, Cihan
|
|
|
|
2 |
p.
|
artikel
|
| 10 |
Anti-TIGIT therapies for solid tumors: a systematic review
|
Rousseau, A.
|
|
|
|
2 |
p.
|
artikel
|
| 11 |
Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline †
|
Grassi, L.
|
|
|
|
2 |
p.
|
artikel
|
| 12 |
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA)
|
Cortesi, L.
|
|
|
|
2 |
p.
|
artikel
|
| 13 |
A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system
|
Coolbrandt, A.
|
|
|
|
2 |
p.
|
artikel
|
| 14 |
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
|
Petrylak, D.P.
|
|
|
|
2 |
p.
|
artikel
|
| 15 |
Area under the curve may hide poor generalisation to external datasets
|
Kleppe, A.
|
|
|
|
2 |
p.
|
artikel
|
| 16 |
Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a pre-screening tool for clinical application
|
Echle, A.
|
|
|
|
2 |
p.
|
artikel
|
| 17 |
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations
|
Villaruz, L.C.
|
|
|
|
2 |
p.
|
artikel
|
| 18 |
A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing
|
Paiella, S.
|
|
|
|
2 |
p.
|
artikel
|
| 19 |
Awareness of predatory publishing
|
Panjikaran, Lloyd
|
|
|
|
2 |
p.
|
artikel
|
| 20 |
Back to the ‘essence’ of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines
|
Eniu, Alexandru
|
|
|
|
2 |
p.
|
artikel
|
| 21 |
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
|
Cremolini, Chiara
|
|
|
|
2 |
p.
|
artikel
|
| 22 |
Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis
|
Caparica, R.
|
|
|
|
2 |
p.
|
artikel
|
| 23 |
Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer
|
Stares, M.
|
|
|
|
2 |
p.
|
artikel
|
| 24 |
Biosimilars as a strategy to improve sustainability
|
Bria, Emilio
|
|
|
|
2 |
p.
|
artikel
|
| 25 |
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy
|
Ortolan, E.
|
|
|
|
2 |
p.
|
artikel
|
| 26 |
Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it
|
Trestini, I.
|
|
|
|
2 |
p.
|
artikel
|
| 27 |
Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion
|
Santini, Daniele
|
|
|
|
2 |
p.
|
artikel
|
| 28 |
Cancer and liver cirrhosis: implications on prognosis and management
|
Pinter, Matthias
|
|
|
|
2 |
p.
|
artikel
|
| 29 |
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective
|
Lambertini, Matteo
|
|
|
|
2 |
p.
|
artikel
|
| 30 |
Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors
|
Lobefaro, R.
|
|
|
|
2 |
p.
|
artikel
|
| 31 |
CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
|
Agostinetto, E.
|
|
|
|
2 |
p.
|
artikel
|
| 32 |
CECOG educational illustrations: the blood–brain barrier and its relevance for targeted cancer therapies and immuno-oncology
|
Preusser, Matthias
|
|
|
|
2 |
p.
|
artikel
|
| 33 |
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
|
Ledermann, J.A.
|
|
|
|
2 |
p.
|
artikel
|
| 34 |
Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey
|
Linardou, H.
|
|
|
|
2 |
p.
|
artikel
|
| 35 |
Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes
|
Yao, Y.
|
|
|
|
2 |
p.
|
artikel
|
| 36 |
Checkpoint inhibitors in the treatment of urological malignancies
|
Popovic, Lazar S.
|
|
|
|
2 |
p.
|
artikel
|
| 37 |
Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan
|
Funakoshi, Taro
|
|
|
|
2 |
p.
|
artikel
|
| 38 |
Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials
|
You, Xia-Hong
|
|
|
|
2 |
p.
|
artikel
|
| 39 |
Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression
|
Seki, Yoshitaka
|
|
|
|
2 |
p.
|
artikel
|
| 40 |
Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer
|
Beije, N.
|
|
|
|
2 |
p.
|
artikel
|
| 41 |
Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
|
Klempner, S.J.
|
|
|
|
2 |
p.
|
artikel
|
| 42 |
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable
|
Ongaro, Elena
|
|
|
|
2 |
p.
|
artikel
|
| 43 |
Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021
|
Grumberg, V.
|
|
|
|
2 |
p.
|
artikel
|
| 44 |
Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned
|
Borgers, J.S.W.
|
|
|
|
2 |
p.
|
artikel
|
| 45 |
Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network
|
Frezza, A.M.
|
|
|
|
2 |
p.
|
artikel
|
| 46 |
Clinical risk factors for ascites in metastatic pancreatic cancer
|
Berger, J.M.
|
|
|
|
2 |
p.
|
artikel
|
| 47 |
Clinical scoring system for the prediction of survival of patients with advanced gastric cancer
|
Kim, Jinchul
|
|
|
|
2 |
p.
|
artikel
|
| 48 |
Clinical value of early detection of circulating tumour DNA-BRAF V600mut in patients with metastatic melanoma treated with a BRAF inhibitor
|
Louveau, Baptiste
|
|
|
|
2 |
p.
|
artikel
|
| 49 |
Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients
|
van Dam, P.A.
|
|
|
|
2 |
p.
|
artikel
|
| 50 |
Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma
|
Lim, KokHaw Jonathan
|
|
|
|
2 |
p.
|
artikel
|
| 51 |
Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
|
Moliner, L.
|
|
|
|
2 |
p.
|
artikel
|
| 52 |
Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?
|
Pellegrino, Benedetta
|
|
|
|
2 |
p.
|
artikel
|
| 53 |
Controversies in upper GI oncology: first-line systemic treatment in MASLD-associated HCC
|
Dekervel, J.
|
|
|
|
2 |
p.
|
artikel
|
| 54 |
Controversies in upper GI oncology: maintenance treatment in pancreatic cancer
|
Dekervel, J.
|
|
|
|
2 |
p.
|
artikel
|
| 55 |
Controversies in upper GI oncology: MSI-H in gastroesophageal adenocarcinoma
|
Petrillo, A.
|
|
|
|
2 |
p.
|
artikel
|
| 56 |
Correction: CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
|
|
|
|
|
2 |
p.
|
artikel
|
| 57 |
Correction: European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis: from ethics to results through the understanding of communication and interaction flows
|
|
|
|
|
2 |
p.
|
artikel
|
| 58 |
Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
|
|
|
|
|
2 |
p.
|
artikel
|
| 59 |
Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations
|
Solomon, B.J.
|
|
|
|
2 |
p.
|
artikel
|
| 60 |
Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’
|
De Angelis, C.
|
|
|
|
2 |
p.
|
artikel
|
| 61 |
Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer”
|
Fumet, Jean-David
|
|
|
|
2 |
p.
|
artikel
|
| 62 |
COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
|
Silvestris, N.
|
|
|
|
2 |
p.
|
artikel
|
| 63 |
Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer
|
Kim, Sun Young
|
|
|
|
2 |
p.
|
artikel
|
| 64 |
Current models, challenges and best practices for work conducted between European academic cooperative groups and industry
|
Stahel, Rolf A.
|
|
|
|
2 |
p.
|
artikel
|
| 65 |
Current standards and practice changing studies in genitourinary (GU) cancers—a review of studies in localized/early GU cancers ☆
|
Tan, W.C.
|
|
|
|
2 |
p.
|
artikel
|
| 66 |
Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab
|
Mountzios, G.
|
|
|
|
2 |
p.
|
artikel
|
| 67 |
Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
|
Berghoff, Anna S.
|
|
|
|
2 |
p.
|
artikel
|
| 68 |
Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology
|
Shibata, H.
|
|
|
|
2 |
p.
|
artikel
|
| 69 |
Discussing and prescribing expensive unfunded anticancer drugs in Australia
|
Karikios, Deme John
|
|
|
|
2 |
p.
|
artikel
|
| 70 |
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards
|
Danesi, R.
|
|
|
|
2 |
p.
|
artikel
|
| 71 |
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment
|
Conte, P.
|
|
|
|
2 |
p.
|
artikel
|
| 72 |
Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy—results of a prospective, multicenter German observational study
|
Li, M.
|
|
|
|
2 |
p.
|
artikel
|
| 73 |
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN ☆
|
Paz-Ares, L.
|
|
|
|
2 |
p.
|
artikel
|
| 74 |
Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials
|
Nassif, E.F.
|
|
|
|
2 |
p.
|
artikel
|
| 75 |
Editorial Board
|
|
|
|
|
2 |
p.
|
artikel
|
| 76 |
Editorial Board
|
|
|
|
|
2 |
p.
|
artikel
|
| 77 |
Editorial Board
|
|
|
|
|
2 |
p.
|
artikel
|
| 78 |
Editorial Board
|
|
|
|
|
2 |
p.
|
artikel
|
| 79 |
Editorial on an international survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
|
Sternberg, Cora N.
|
|
|
|
2 |
p.
|
artikel
|
| 80 |
Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18
|
Minichsdorfer, C.
|
|
|
|
2 |
p.
|
artikel
|
| 81 |
Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis
|
Landré, T.
|
|
|
|
2 |
p.
|
artikel
|
| 82 |
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
|
Tomita, Y.
|
|
|
|
2 |
p.
|
artikel
|
| 83 |
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)
|
Orditura, Michele
|
|
|
|
2 |
p.
|
artikel
|
| 84 |
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
|
De Angelis, C.
|
|
|
|
2 |
p.
|
artikel
|
| 85 |
Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’
|
Cantini, L.
|
|
|
|
2 |
p.
|
artikel
|
| 86 |
Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’
|
Lee, R.J.
|
|
|
|
2 |
p.
|
artikel
|
| 87 |
Erratum to ‘Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients’
|
Beechinor, R.
|
|
|
|
2 |
p.
|
artikel
|
| 88 |
ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective
|
Koessler, T.
|
|
|
|
2 |
p.
|
artikel
|
| 89 |
ESMO Copenhagen 2016: a lung cancer ‘grand cru’
|
Douillard, Jean-Yves
|
|
|
|
2 |
p.
|
artikel
|
| 90 |
ESMO presidential symposium wrap up: the ClarIDHy trial
|
Abou-Alfa, Ghassan K.
|
|
|
|
2 |
p.
|
artikel
|
| 91 |
European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer
|
Stanel, Stefan Cristian
|
|
|
|
2 |
p.
|
artikel
|
| 92 |
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario ☆
|
Cantini, L.
|
|
|
|
2 |
p.
|
artikel
|
| 93 |
Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma
|
Peeters, Marc
|
|
|
|
2 |
p.
|
artikel
|
| 94 |
External quality assessment for EGFR mutations in Italy: improvements in performances over the time
|
Normanno, Nicola
|
|
|
|
2 |
p.
|
artikel
|
| 95 |
Extrapolation concept at work with biosimilar: a decade of experience in oncology
|
Krendyukov, Andriy
|
|
|
|
2 |
p.
|
artikel
|
| 96 |
Factors associated with treatment delay in women with primary breast cancer who were referred to reproductive specialists
|
Kitano, Atsuko
|
|
|
|
2 |
p.
|
artikel
|
| 97 |
Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’
|
De Falco, Vincenzo
|
|
|
|
2 |
p.
|
artikel
|
| 98 |
First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors
|
Zheng, Y.
|
|
|
|
2 |
p.
|
artikel
|
| 99 |
First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience
|
Jeryczynski, G.
|
|
|
|
2 |
p.
|
artikel
|
| 100 |
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
|
Punt, C.J.A.
|
|
|
|
2 |
p.
|
artikel
|
| 101 |
FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
|
Cervantes, A.
|
|
|
|
2 |
p.
|
artikel
|
| 102 |
Gender climate in Indian oncology: national survey report
|
Bajpai, Jyoti
|
|
|
|
2 |
p.
|
artikel
|
| 103 |
Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)
|
Elez, E.
|
|
|
|
2 |
p.
|
artikel
|
| 104 |
Gender oncology: recommendations and consensus of the Italian Association of Medical Oncology (AIOM)
|
Berardi, R.
|
|
|
|
2 |
p.
|
artikel
|
| 105 |
Genomic-guided precision therapy for soft tissue sarcoma
|
Chen, Hsing-Wu
|
|
|
|
2 |
p.
|
artikel
|
| 106 |
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
|
Rodriguez-Freixinos, Victor
|
|
|
|
2 |
p.
|
artikel
|
| 107 |
Global cancer control: responding to the growing burden, rising costs and inequalities in access
|
Prager, Gerald W.
|
|
|
|
2 |
p.
|
artikel
|
| 108 |
Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers
|
Samani, A.
|
|
|
|
2 |
p.
|
artikel
|
| 109 |
How I treat endocrine-dependent metastatic breast cancer
|
Gombos, A.
|
|
|
|
2 |
p.
|
artikel
|
| 110 |
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
|
Morganti, S.
|
|
|
|
2 |
p.
|
artikel
|
| 111 |
How to use liquid biopsies to treat patients with cancer
|
De Mattos-Arruda, L.
|
|
|
|
2 |
p.
|
artikel
|
| 112 |
How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain
|
Castañeda, A.
|
|
|
|
2 |
p.
|
artikel
|
| 113 |
Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
|
Guida, M.
|
|
|
|
2 |
p.
|
artikel
|
| 114 |
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies
|
Amoroso, V.
|
|
|
|
2 |
p.
|
artikel
|
| 115 |
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
|
Lasagna, A.
|
|
|
|
2 |
p.
|
artikel
|
| 116 |
Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10
|
Grieve, Stacy
|
|
|
|
2 |
p.
|
artikel
|
| 117 |
Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT)
|
Gridelli, C.
|
|
|
|
2 |
p.
|
artikel
|
| 118 |
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
|
Ueno, Takayuki
|
|
|
|
2 |
p.
|
artikel
|
| 119 |
Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network
|
Morgan, G.
|
|
|
|
2 |
p.
|
artikel
|
| 120 |
Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients
|
Armbrust, R.
|
|
|
|
2 |
p.
|
artikel
|
| 121 |
Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer
|
Yao, W.
|
|
|
|
2 |
p.
|
artikel
|
| 122 |
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
|
de With, M.
|
|
|
|
2 |
p.
|
artikel
|
| 123 |
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
|
Ree, Anne Hansen
|
|
|
|
2 |
p.
|
artikel
|
| 124 |
Indications regarding the management of interventional clinical trials with drugs during the current COVID-19 emergency in Italy
|
Pinto, Carmine
|
|
|
|
2 |
p.
|
artikel
|
| 125 |
Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
|
Fujiwara, Yutaka
|
|
|
|
2 |
p.
|
artikel
|
| 126 |
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
|
Sastre, J.
|
|
|
|
2 |
p.
|
artikel
|
| 127 |
International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
|
Liede, Alexander
|
|
|
|
2 |
p.
|
artikel
|
| 128 |
In the literature: April 2020
|
Gambardella, Valentina
|
|
|
|
2 |
p.
|
artikel
|
| 129 |
In the literature: April 2017
|
Cervantes, Andrés
|
|
|
|
2 |
p.
|
artikel
|
| 130 |
In the literature: April 2019
|
Bruxiola, Gema
|
|
|
|
2 |
p.
|
artikel
|
| 131 |
In the literature: February 2022
|
Gambardella, V.
|
|
|
|
2 |
p.
|
artikel
|
| 132 |
In the literature: February 2018
|
Cervantes, Andrés
|
|
|
|
2 |
p.
|
artikel
|
| 133 |
In the literature: February 2021
|
Cejalvo, J.M.
|
|
|
|
2 |
p.
|
artikel
|
| 134 |
In the literature: March 2016
|
Cervantes, A.
|
|
|
|
2 |
p.
|
artikel
|
| 135 |
In the Literature: March 2023
|
Gambardella, V.
|
|
|
|
2 |
p.
|
artikel
|
| 136 |
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
|
Krebs, M.G.
|
|
|
|
2 |
p.
|
artikel
|
| 137 |
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes
|
Franzoi, M.A.
|
|
|
|
2 |
p.
|
artikel
|
| 138 |
Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?
|
Benvenuti, C.
|
|
|
|
2 |
p.
|
artikel
|
| 139 |
Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology
|
Giuliani, Rosa
|
|
|
|
2 |
p.
|
artikel
|
| 140 |
Lenvatinib plus pembrolizumab a new effective combination of targeted agents
|
Perez-Fidalgo, J.A.
|
|
|
|
2 |
p.
|
artikel
|
| 141 |
Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer
|
Eiger, Daniel
|
|
|
|
2 |
p.
|
artikel
|
| 142 |
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
|
Park, H.S.
|
|
|
|
2 |
p.
|
artikel
|
| 143 |
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
|
König, D.
|
|
|
|
2 |
p.
|
artikel
|
| 144 |
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
|
Girard, N.
|
|
|
|
2 |
p.
|
artikel
|
| 145 |
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival
|
Miglietta, F.
|
|
|
|
2 |
p.
|
artikel
|
| 146 |
Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis
|
Palazzo, A.
|
|
|
|
2 |
p.
|
artikel
|
| 147 |
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
|
Buske, C.
|
|
|
|
2 |
p.
|
artikel
|
| 148 |
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
|
Herrstedt, J.
|
|
|
|
2 |
p.
|
artikel
|
| 149 |
Maximising clinical benefit with adequate patient management beyond the second line in mCRC
|
Argiles, Guillem
|
|
|
|
2 |
p.
|
artikel
|
| 150 |
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
|
Granier, Clemence
|
|
|
|
2 |
p.
|
artikel
|
| 151 |
Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial
|
Camerini, A.
|
|
|
|
2 |
p.
|
artikel
|
| 152 |
Moving cancer care closer to home: a single-centre experience of home chemotherapy administration for patients with myelodysplastic syndrome
|
Murthy, Vidhya
|
|
|
|
2 |
p.
|
artikel
|
| 153 |
Moving to ultra-short therapy to cure patients with cancer: a solution for sustainable cancer care
|
Ribeiro, J.M.
|
|
|
|
2 |
p.
|
artikel
|
| 154 |
MRI-based contrast clearance analysis shows high differentiation accuracy between radiation-induced reactions and progressive disease after cranial radiotherapy
|
Bodensohn, R.
|
|
|
|
2 |
p.
|
artikel
|
| 155 |
Multiple primary tumours: challenges and approaches, a review
|
Vogt, Alexia
|
|
|
|
2 |
p.
|
artikel
|
| 156 |
Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors
|
Dufresne, A.
|
|
|
|
2 |
p.
|
artikel
|
| 157 |
Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
|
Sinn, K.
|
|
|
|
2 |
p.
|
artikel
|
| 158 |
Neoadjuvant radiotherapy in the approach of locally advanced breast cancer
|
Sousa, Cláudia
|
|
|
|
2 |
p.
|
artikel
|
| 159 |
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer
|
Badora-Rybicka, Agnieszka
|
|
|
|
2 |
p.
|
artikel
|
| 160 |
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis
|
Orditura, Michele
|
|
|
|
2 |
p.
|
artikel
|
| 161 |
New emerging targets in cancer immunotherapy: the role of LAG3
|
Puhr, Hannah Christina
|
|
|
|
2 |
p.
|
artikel
|
| 162 |
New horizon in breast cancer therapy: highlights from the European Society for Medical Oncology
|
Senkus, Elżbieta
|
|
|
|
2 |
p.
|
artikel
|
| 163 |
New targets, new hopes
|
Strijbos, M.
|
|
|
|
2 |
p.
|
artikel
|
| 164 |
New treatment options for metastatic renal cell carcinoma
|
Rodriguez-Vida, Alejo
|
|
|
|
2 |
p.
|
artikel
|
| 165 |
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
|
Amatu, Alessio
|
|
|
|
2 |
p.
|
artikel
|
| 166 |
Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chiricuţă Oncology Institute series
|
Preda, A.
|
|
|
|
2 |
p.
|
artikel
|
| 167 |
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
|
Senan, S.
|
|
|
|
2 |
p.
|
artikel
|
| 168 |
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial
|
Michels, S.
|
|
|
|
2 |
p.
|
artikel
|
| 169 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
|
Shitara, K.
|
|
|
|
2 |
p.
|
artikel
|
| 170 |
Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel
|
Mauri, Davide
|
|
|
|
2 |
p.
|
artikel
|
| 171 |
Patient-reported tolerability of adverse events in phase 1 trials
|
Henon, Clémence
|
|
|
|
2 |
p.
|
artikel
|
| 172 |
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)
|
Moreau-Bachelard, C.
|
|
|
|
2 |
p.
|
artikel
|
| 173 |
Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors
|
Wang, R.
|
|
|
|
2 |
p.
|
artikel
|
| 174 |
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases
|
Hecht, J.R.
|
|
|
|
2 |
p.
|
artikel
|
| 175 |
Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases
|
Jansen, Yanina J.L.
|
|
|
|
2 |
p.
|
artikel
|
| 176 |
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers
|
Tabernero, J.
|
|
|
|
2 |
p.
|
artikel
|
| 177 |
Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma
|
Laganà, M.
|
|
|
|
2 |
p.
|
artikel
|
| 178 |
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
|
Takahashi, T.
|
|
|
|
2 |
p.
|
artikel
|
| 179 |
Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors
|
Perez, B.
|
|
|
|
2 |
p.
|
artikel
|
| 180 |
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
|
Moore, Kathleen N.
|
|
|
|
2 |
p.
|
artikel
|
| 181 |
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas
|
Fiedler, Walter
|
|
|
|
2 |
p.
|
artikel
|
| 182 |
Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers
|
Zhou, C.
|
|
|
|
2 |
p.
|
artikel
|
| 183 |
Postgraduate oncology educational shifts during the COVID-19 pandemic: results of faculty and medical student surveys
|
Moya-Plana, A.
|
|
|
|
2 |
p.
|
artikel
|
| 184 |
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
|
Gouda, M.A.
|
|
|
|
2 |
p.
|
artikel
|
| 185 |
Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer
|
Bijlsma, Rhode
|
|
|
|
2 |
p.
|
artikel
|
| 186 |
Prevalence and factors associated with professional burnout in Polish oncologists—results of a nationwide survey
|
Sobczuk, P.
|
|
|
|
2 |
p.
|
artikel
|
| 187 |
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study
|
Borelli, B.
|
|
|
|
2 |
p.
|
artikel
|
| 188 |
Prognostic evaluation in patients with advanced cancer in the last months of life: ESMO Clinical Practice Guideline ☆
|
Stone, P.
|
|
|
|
2 |
p.
|
artikel
|
| 189 |
Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
|
Fountzilas, Elena
|
|
|
|
2 |
p.
|
artikel
|
| 190 |
Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer
|
Vardy, Janette L.
|
|
|
|
2 |
p.
|
artikel
|
| 191 |
Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis
|
Li, Jinluan
|
|
|
|
2 |
p.
|
artikel
|
| 192 |
Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
|
Matikas, A.
|
|
|
|
2 |
p.
|
artikel
|
| 193 |
Prospective analysis of 895 patients on a UK Genomics Review Board
|
Moore, David Allan
|
|
|
|
2 |
p.
|
artikel
|
| 194 |
Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial
|
Siena, Salvatore
|
|
|
|
2 |
p.
|
artikel
|
| 195 |
Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists
|
Meattini, Icro
|
|
|
|
2 |
p.
|
artikel
|
| 196 |
223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy
|
Anderson, Pete M.
|
|
|
|
2 |
p.
|
artikel
|
| 197 |
Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery
|
El Hajj, H.
|
|
|
|
2 |
p.
|
artikel
|
| 198 |
Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU)
|
Casali, Paolo G.
|
|
|
|
2 |
p.
|
artikel
|
| 199 |
Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer ☆
|
Martens, G.A.
|
|
|
|
2 |
p.
|
artikel
|
| 200 |
Real-world data in oncology: a questionnaire-based analysis of the academic research landscape examining the policies and experiences of the cancer cooperative groups
|
Saesen, R.
|
|
|
|
2 |
p.
|
artikel
|
| 201 |
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study
|
Procopio, G.
|
|
|
|
2 |
p.
|
artikel
|
| 202 |
Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer
|
Heitzer, E.
|
|
|
|
2 |
p.
|
artikel
|
| 203 |
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
|
Grande, E.
|
|
|
|
2 |
p.
|
artikel
|
| 204 |
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer
|
Morgillo, Floriana
|
|
|
|
2 |
p.
|
artikel
|
| 205 |
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
|
Ruiz-Bañobre, J.
|
|
|
|
2 |
p.
|
artikel
|
| 206 |
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
|
Cascone, T.
|
|
|
|
2 |
p.
|
artikel
|
| 207 |
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
|
Rudin, C.M.
|
|
|
|
2 |
p.
|
artikel
|
| 208 |
Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study
|
Sherman, E.
|
|
|
|
2 |
p.
|
artikel
|
| 209 |
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
|
Ochsenreither, S.
|
|
|
|
2 |
p.
|
artikel
|
| 210 |
Safety, tolerability and clinical implementation of ‘ready-to-use’ 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
|
Manoharan, Prakash
|
|
|
|
2 |
p.
|
artikel
|
| 211 |
S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial
|
Watanabe, J.
|
|
|
|
2 |
p.
|
artikel
|
| 212 |
Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer
|
Morgan, Robert D.
|
|
|
|
2 |
p.
|
artikel
|
| 213 |
Sex and gender perspectives in colorectal cancer
|
Baraibar, I.
|
|
|
|
2 |
p.
|
artikel
|
| 214 |
Sexual quality of life of adolescents and young adult breast cancer survivors
|
Vrancken Peeters, N.J.M.C.
|
|
|
|
2 |
p.
|
artikel
|
| 215 |
Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit
|
Mulder, J.
|
|
|
|
2 |
p.
|
artikel
|
| 216 |
Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting
|
Nakayama, Izuma
|
|
|
|
2 |
p.
|
artikel
|
| 217 |
Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis
|
Ding, Y.
|
|
|
|
2 |
p.
|
artikel
|
| 218 |
Small-cell lung cancer in never-smokers
|
Torres-Durán, M.
|
|
|
|
2 |
p.
|
artikel
|
| 219 |
Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy
|
Berardi, R.
|
|
|
|
2 |
p.
|
artikel
|
| 220 |
STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort
|
Papillon-Cavanagh, Simon
|
|
|
|
2 |
p.
|
artikel
|
| 221 |
Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
|
Guarneri, V.
|
|
|
|
2 |
p.
|
artikel
|
| 222 |
Survival impact of post-operative immunotherapy in resected stage III cutaneous melanomas in the checkpoint era
|
Hagopian, G.
|
|
|
|
2 |
p.
|
artikel
|
| 223 |
Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
|
Oing, C.
|
|
|
|
2 |
p.
|
artikel
|
| 224 |
Table of Contents
|
|
|
|
|
2 |
p.
|
artikel
|
| 225 |
Table of Contents
|
|
|
|
|
2 |
p.
|
artikel
|
| 226 |
Table of Contents
|
|
|
|
|
2 |
p.
|
artikel
|
| 227 |
Table of Contents
|
|
|
|
|
2 |
p.
|
artikel
|
| 228 |
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
|
Schettini, F.
|
|
|
|
2 |
p.
|
artikel
|
| 229 |
Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
|
Błaszkowska, M.
|
|
|
|
2 |
p.
|
artikel
|
| 230 |
2017 Thank you to our reviewers
|
|
|
|
|
2 |
p.
|
artikel
|
| 231 |
The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study
|
Izawa, N.
|
|
|
|
2 |
p.
|
artikel
|
| 232 |
The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study
|
Yi, L.
|
|
|
|
2 |
p.
|
artikel
|
| 233 |
The DNA damage response network in the treatment of head and neck squamous cell carcinoma
|
Psyrri, A.
|
|
|
|
2 |
p.
|
artikel
|
| 234 |
The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer
|
De Santis, Maria
|
|
|
|
2 |
p.
|
artikel
|
| 235 |
The effect of adjuvant chemotherapy in male breast cancer: 134 cases from a retrospective study
|
Yu, Xing-Fei
|
|
|
|
2 |
p.
|
artikel
|
| 236 |
The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
|
Delgado, J.
|
|
|
|
2 |
p.
|
artikel
|
| 237 |
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements
|
Delgado, J.
|
|
|
|
2 |
p.
|
artikel
|
| 238 |
“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores
|
Cherny, N.I.
|
|
|
|
2 |
p.
|
artikel
|
| 239 |
The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration
|
Banerjee, S.
|
|
|
|
2 |
p.
|
artikel
|
| 240 |
The increasing burden of testicular seminomas and non-seminomas in adolescents and young adults (AYAs): incidence, treatment, disease-specific survival and mortality trends in the Netherlands between 1989 and 2019
|
van der Meer, D.J.
|
|
|
|
2 |
p.
|
artikel
|
| 241 |
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
|
Banna, G.L.
|
|
|
|
2 |
p.
|
artikel
|
| 242 |
The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer—results from the RAPIDO trial
|
Dijkstra, E.A.
|
|
|
|
2 |
p.
|
artikel
|
| 243 |
Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries
|
Post, H.C.
|
|
|
|
2 |
p.
|
artikel
|
| 244 |
Towards the era of precision medicine in metastatic colorectal cancer
|
Napolitano, Stefania
|
|
|
|
2 |
p.
|
artikel
|
| 245 |
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis ☆
|
Michelon, I.
|
|
|
|
2 |
p.
|
artikel
|
| 246 |
Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies
|
Li, J.
|
|
|
|
2 |
p.
|
artikel
|
| 247 |
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma ☆
|
Geurts, Y.M.
|
|
|
|
2 |
p.
|
artikel
|
| 248 |
Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
|
Corti, C.
|
|
|
|
2 |
p.
|
artikel
|
| 249 |
Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases
|
Steindl, A.
|
|
|
|
2 |
p.
|
artikel
|
| 250 |
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
|
Kitano, Atsuko
|
|
|
|
2 |
p.
|
artikel
|
| 251 |
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era
|
Toss, A.
|
|
|
|
2 |
p.
|
artikel
|
| 252 |
Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations
|
Oizumi, Satoshi
|
|
|
|
2 |
p.
|
artikel
|
| 253 |
Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome
|
Puhr, Hannah Christina
|
|
|
|
2 |
p.
|
artikel
|
| 254 |
Where do they come from? A call for complete transparency regarding the origin of human tissues in research
|
Hildebrandt, Sabine
|
|
|
|
2 |
p.
|
artikel
|
| 255 |
Will CHRYSALIS turn into a butterfly?
|
Fuereder, T.
|
|
|
|
2 |
p.
|
artikel
|
Tijdschrift beschrijving